Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards

On May 27, 2025, Oragenics, Inc. (the “ Company ”) filed Articles of Amendment (the “ Amendment ”) to its Amended and Restated Articles of Incorporation, as amended, with the Secretary of State of Florida to effect a One-for-Thirty (1-for-30) reverse stock split (the “ Reverse Stock Split ”) of the Company’s shares of Common Stock, $0.001, par value (the “ Common Stock ”). The Company anticipates that the Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 3, 2025 (the “ Effective Time”) and that the Common Stock will be quoted on NYSE American Stock Market (the “ NYSE American ”) on a post-split basis at the open of business on June 3, 2025. The Company’s shareholders approved the Reverse Stock Split at the Company’s 2024 Annual Meeting of Stockholders held on May 2, 2025, at a ratio between One-for-Five (1-for 5) to One-for Fifty (1-for-50), with such ratio to be determined in the discretion of the Company’s Board of Directors (the “ Board ”) and with such re